Pallas Capital Advisors LLC Has $992,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Pallas Capital Advisors LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 270.6% in the 1st quarter, Holdings Channel.com reports. The firm owned 5,629 shares of the medical research company’s stock after buying an additional 4,110 shares during the quarter. Pallas Capital Advisors LLC’s holdings in IQVIA were worth $992,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. American National Bank & Trust acquired a new position in shares of IQVIA in the 1st quarter valued at approximately $26,000. ST Germain D J Co. Inc. raised its stake in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of IQVIA during the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA during the 4th quarter worth approximately $44,000. Finally, Zions Bancorporation N.A. raised its stake in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Robert W. Baird dropped their price objective on IQVIA from $195.00 to $161.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. decreased their price objective on IQVIA from $232.00 to $177.00 and set an “overweight” rating on the stock in a report on Monday, May 19th. Citigroup reaffirmed a “neutral” rating on shares of IQVIA in a research note on Thursday, May 22nd. Hsbc Global Res lowered IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Finally, Truist Financial reduced their price objective on IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a research note on Thursday, April 10th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $226.32.

IQVIA Trading Up 3.6%

Shares of IQV stock opened at $159.70 on Wednesday. The company has a market cap of $27.63 billion, a P/E ratio of 21.29, a PEG ratio of 1.99 and a beta of 1.28. The stock has a 50 day simple moving average of $147.13 and a two-hundred day simple moving average of $178.43. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the previous year, the company posted $2.54 earnings per share. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.